Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

This study is testing CD19-targeted CAR-T cell therapy — a powerful immune cell treatment originally developed for blood cancers — to see if it can treat severe, treatment-resistant autoimmune diseases by resetting the immune system. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of one of the following: Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis (scleroderma), Dermatomyositis with a positive myositis antibody, or ANCA-associated vasculitis - Your disease is still active despite at least two prior treatments - Your organ function is adequate **You may NOT be eligible if...** - You have a serious active infection - You have significant heart, liver, or kidney failure - You have a history of or current cancer - You are pregnant or breastfeeding - You are unwilling to use contraception during the study Talk to your doctor to see if this trial is right for you.